WealthTrust Asset Management LLC Has $105,000 Stock Holdings in Sight Sciences, Inc. (NASDAQ:SGHT)

WealthTrust Asset Management LLC grew its position in Sight Sciences, Inc. (NASDAQ:SGHT) by 230.2% in the first quarter, according to its most recent filing with the SEC. The fund owned 43,590 shares of the company’s stock after acquiring an additional 30,390 shares during the period. WealthTrust Asset Management LLC owned 0.08% of Sight Sciences worth $105,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. Foster Victor Wealth Advisors LLC bought a new position in shares of Sight Sciences in the 1st quarter valued at $85,000. B. Riley Wealth Advisors Inc. lifted its stake in shares of Sight Sciences by 24.6% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 243,082 shares of the company’s stock valued at $885,000 after acquiring an additional 48,000 shares during the last quarter. Squarepoint Ops LLC lifted its stake in shares of Sight Sciences by 314.2% in the 4th quarter. Squarepoint Ops LLC now owns 169,211 shares of the company’s stock valued at $616,000 after acquiring an additional 128,355 shares during the last quarter. ProShare Advisors LLC bought a new position in Sight Sciences during the 4th quarter worth $36,000. Finally, Prosight Management LP raised its position in Sight Sciences by 71.1% during the 4th quarter. Prosight Management LP now owns 908,847 shares of the company’s stock worth $3,308,000 after purchasing an additional 377,625 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SGHT. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 target price (up from $3.50) on shares of Sight Sciences in a research report on Wednesday, June 18th. Lake Street Capital raised their target price on Sight Sciences from $2.50 to $3.00 and gave the stock a “hold” rating in a research report on Friday, May 9th. Citigroup reaffirmed a “neutral” rating and set a $3.60 target price (up from $3.20) on shares of Sight Sciences in a research report on Thursday, May 22nd. Finally, Wall Street Zen raised Sight Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 28th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $4.10.

Sight Sciences Stock Performance

SGHT stock opened at $3.41 on Friday. The stock has a 50-day moving average price of $3.74 and a 200-day moving average price of $3.14. Sight Sciences, Inc. has a 1-year low of $2.03 and a 1-year high of $8.45. The company has a current ratio of 10.47, a quick ratio of 9.99 and a debt-to-equity ratio of 0.51. The firm has a market cap of $176.30 million, a PE ratio of -3.48 and a beta of 2.47.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Thursday, May 8th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.01. The company had revenue of $17.51 million during the quarter, compared to the consensus estimate of $16.51 million. Sight Sciences had a negative return on equity of 54.62% and a negative net margin of 63.24%. As a group, equities research analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Insider Activity

In other news, CEO Paul Badawi sold 23,637 shares of the firm’s stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $4.15, for a total value of $98,093.55. Following the completion of the sale, the chief executive officer directly owned 5,986,943 shares in the company, valued at $24,845,813.45. This trade represents a 0.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Jeremy B. Hayden sold 9,160 shares of the firm’s stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $4.17, for a total value of $38,197.20. Following the completion of the sale, the insider owned 266,321 shares of the company’s stock, valued at approximately $1,110,558.57. This represents a 3.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,365 shares of company stock valued at $180,017. 30.90% of the stock is currently owned by company insiders.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.